HLTH event announcements show how AI and wearables are changing the economics of healthcare

HLTH USA 2026 brought healthcare, tech, and pharma leaders to Las Vegas this week for one of the year’s most influential health-tech gatherings. We tracked the event remotely and picked the three developments with the clearest implications for health and pharma marketers, along with what each means for your strategy in the year ahead.

1. Apple, OpenEvidence pilot an AI health advisor built on clinical evidence

The companies are jointly conducting a research study in which users can ask health questions in an experimental app and connect personal data for more personalized answers. The study is open to up to 200,000 eligible US adults ages 21 and older with an Apple Intelligence-enabled iPhone, per an Apple newsroom announcement.

Health is the fastest-growing consumer AI use case this year, per our projections, giving Apple a strong incentive to enter the AI health chatbot market. Rather than rush in, Apple is taking a cautious approach with a year-long study focused on clinical accuracy and safeguards. Its partner, OpenEvidence, is a leading physician-focused AI platform that draws on peer-reviewed medical literature.

Apple can afford to take its time. Its device-driven business and lucrative services ecosystem give it the flexibility to study consumer behavior and refine a potential AI health offering. That flexibility matters as tech and AI giants like Google and OpenAI face lawsuits alleging their general-purpose chatbots provided unsafe medical advice or drove users to self-harm.

Apple’s exploration of the AI health market shows that AI-powered health guidance could reach a broader consumer audience. Pharma brands should prioritize authoritative, AI-discoverable content so their treatments are accurately represented in AI-generated answers.

2. Noom bets that owning the wearable beats borrowing one

Starting next year, Noom will include Noom Band in obesity care programs for existing employer and health plan clients at no additional cost. The screenless, wrist-worn band is designed to capture measurements related to weight management and metabolic health. It will run on the biometric platform Sensor Bio, whose wearable sensors track heart rate, heart rate variability, SpO2, sleep, and activity.

Noom is positioning wearables as a way to improve GLP-1 outcomes and help employers and health plans manage treatment costs. The company says GLP-1 users who connected a wearable were 34% more likely to lose 20 pounds within four months than those who didn’t. For pharma marketers in obesity and metabolic health, such data could strengthen the case for payer coverage by demonstrating how device-supported care can improve GLP-1 treatment outcomes.

For digital health brands, Noom Band will test whether developing an in-house wearable pays off for consumer health companies and providers versus subsidizing established wearable products. Hims & Hers is also considering its own wearable launch. Although the Noom app already connects to popular wearables, fewer than 10% of members own devices like Oura Ring or Whoop, Noom CEO Geoff Cook told Fierce Healthcare. Offering a wearable at no additional upfront cost could remove a key adoption barrier while giving Noom greater control over health data and how it’s used to drive behavior change.

3. OpenAI expands AI agents that automate healthcare administrative tasks

New computer-use capabilities will allow AI agents to navigate electronic health records (EHRs), insurer portals, and other software to complete multistep clinical and administrative workflows, including prior authorizations, referrals, and discharge planning. Partners including CVS Health, Cigna, Abridge, and Ambience are developing or deploying the technology.

In one example OpenAI cited, staff manually retrieve patient records and enter information into insurer portals to secure MRI prior authorization. AI agents can automate these tasks by navigating applications, clicking, and typing. CVS said one agent cleared a months-long document backlog over a weekend.

Pharma teams focused on market access, patient hub services, and healthcare professional education should track how AI agents automate the administrative steps between prescribing and treatment access. As payers and pharmacy chains embed AI agents into daily workflows, pharma marketers should audit how their brand's formulary status, copay cards, and affordability programs appear inside these automated pipelines. Coming just days after Google's Gemini for Healthcare launch, OpenAI’s announcement reflects intensifying competition among tech giants and specialized vendors for the health systems and payers that sit between pharma brands and patients.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.

You've read 0 of 2 free articles this month.

Get more articles - create your free account today!